The African Trypanosomiasis drugs in development market research report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for African Trypanosomiasis. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for African Trypanosomiasis by 16 companies/universities/institutes. The top development phase for African Trypanosomiasis is preclinical with nine drugs in that stage. The African Trypanosomiasis pipeline has eight drugs in development by companies and nine by universities/ institutes. Some of the companies in the African Trypanosomiasis pipeline products market are: University of Dundee, University of Edinburgh and University of Glasgow.
The key targets in the African Trypanosomiasis pipeline products market include Glycylpeptide N Tetradecanoyltransferase, Lanosterol 14 Alpha Demethylase, and Adenosylmethionine Decarboxylase.
The key mechanisms of action in the African Trypanosomiasis pipeline product include Glycylpeptide N Tetradecanoyltransferase Inhibitor with two drugs in Preclinical. The African Trypanosomiasis pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the African Trypanosomiasis pipeline products market including Small Molecule, and Peptide.
African Trypanosomiasis overview
African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, weakness, and a swollen, red, painful nodule at the site of the fly bite. Treatment includes anti-protozoal agents.
For a complete picture of African Trypanosomiasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
